ANS is committed to advancing, fostering, and promoting the development and application of nuclear sciences and technologies to benefit society.
Explore the many uses for nuclear science and its impact on energy, the environment, healthcare, food, and more.
Explore membership for yourself or for your organization.
Conference Spotlight
2026 Nuclear Energy Conference & Expo (NECX)
August 24–27, 2026
Dallas, TX|Hilton Anatole
Latest Magazine Issues
Aug 2026
Jan 2026
2026
Latest Journal Issues
Nuclear Science and Engineering
October 2026
Nuclear Technology
September 2026
Fusion Science and Technology
August 2026
Latest News
Second round of Launch Pad selections includes eight newcomers
The National Reactor Innovation Center at Idaho National Laboratory has announced 13 project selections across 12 companies for the Nuclear Energy Launch Pad, a Department of Energy–led program that integrates reactor and fuel facility authorization, testing, and deployment support for private nuclear developers.
The Launch Pad emerged from the Reactor Pilot Program and Fuel Line Pilot Program.
According to INL, projects selected include reactor development and nuclear fuel cycle advancements, including fabrication, enrichment, and conversion technologies.
Greg Staack, Yung-Sung Cheng, Yue Zhou, Tom LaBone
Fusion Science and Technology | Volume 71 | Number 4 | May 2017 | Pages 570-574
Technical Note | doi.org/10.1080/15361055.2017.1291041
Articles are hosted by Taylor and Francis Online.
Samples of tritiated LaNi4.15Al0.85 (LANA.85) and 13X zeolite were analyzed to obtain particle size distributions and tritium evolution rates in a simulated lung environment. This information was used to calculate intake-to-dose conversion factors (DCFs), which estimate the committed effective dose (CED) a worker would receive after inhaling either tritiated particulate. The DCFs for tritiated LANA.85 and 13X particulate with a default activity mean aerodynamic diameter (AMAD) of 5 μm were determined to be 1.01E-11 Sv/Bq and 1.11E-11 Sv/Bq, respectively. These results are comparable to that of HTO, 1.8E-11 Sv/Bq, indicating that urine bioassay results can conservatively estimate the dose delivered if the worker was exposed to any mixture of HTO, LANA.85, or 13X.
